{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-000163","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.054529+00:00","generated_at":"2026-06-27T19:32:00.907076+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Beam Therapeutics enters $1.35B collaboration with Pfizer for in vivo base editing programs","bullets":["Exclusive 4-year collaboration with Pfizer on 3 rare disease targets (liver, muscle, CNS).","$300M upfront; eligible for up to $1.35B milestones plus royalties.","Preliminary cash: ~$0.9B actual, $1.2B pro forma including $300M upfront.","First subject enrollment in BEAM-101 Phase 1/2 trial for sickle cell disease expected H2 2022.","BEAM-301 (GSDIa) named fourth dev candidate; IND-enabling studies planned in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-000163","json":"https://secwatch.observer/filing/0000950170-22-000163.json","markdown":"https://secwatch.observer/filing/0000950170-22-000163.md","text":"https://secwatch.observer/filing/0000950170-22-000163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022000163/0000950170-22-000163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022000163/beam-20220109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:32:00.907076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}